Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Have Mutation, Will Travel Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology

Have Mutation, Will Travel Utilizing Online Patient Communities and New Trial Strategies to... EDITORIAL Have Mutation, Will Travel Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology Howard (Jack) West, MD,* and D. Ross Camidge, MD, PhD† ur conceptualization of oncology is undergoing a revolutionary transition based on Oadvances in the molecular categorization of cancer. This recognition of the impor- tance of molecular diversity has led to clear advances not just in the understanding of, but in the targeted treatment for, specific and increasingly narrow subtypes of many cancers. Using lung cancer as an example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors or crizotinib have been clearly demonstrated to produce response rates in the 60 to 75% range and prolonged progression-free survival in the range of 9 to 13 1–4 months when given to patients with an activating EGFR mutation or anaplastic lymphoma kinase (ALK) translocation, respectively. Although these results represent treatment breakthroughs for subgroups of patients, the implications for clinical research focusing on cancer patient subpopulations are only just becoming apparent. The frequency of EGFR mutations varies geographically but is present in only approximately 10 to 15% of the Caucasian lung cancer population. ALK gene rearrange- ments are present in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Have Mutation, Will Travel Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology

Camidge, D. Ross
Journal of Thoracic Oncology , Volume 7 (3) – Mar 1, 2012
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/have-mutation-will-travel-utilizing-online-patient-communities-and-new-kOaLMj829c

References (11)

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182432646
pmid
22334010
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Have Mutation, Will Travel Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology Howard (Jack) West, MD,* and D. Ross Camidge, MD, PhD† ur conceptualization of oncology is undergoing a revolutionary transition based on Oadvances in the molecular categorization of cancer. This recognition of the impor- tance of molecular diversity has led to clear advances not just in the understanding of, but in the targeted treatment for, specific and increasingly narrow subtypes of many cancers. Using lung cancer as an example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors or crizotinib have been clearly demonstrated to produce response rates in the 60 to 75% range and prolonged progression-free survival in the range of 9 to 13 1–4 months when given to patients with an activating EGFR mutation or anaplastic lymphoma kinase (ALK) translocation, respectively. Although these results represent treatment breakthroughs for subgroups of patients, the implications for clinical research focusing on cancer patient subpopulations are only just becoming apparent. The frequency of EGFR mutations varies geographically but is present in only approximately 10 to 15% of the Caucasian lung cancer population. ALK gene rearrange- ments are present in

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2012

There are no references for this article.